Laurus Labs and IIT Kanpur partner for new gene therapy products

Indian pharmaceutical company Laurus Labs has signed a memorandum of agreement (MoA) with the Indian Institute of Technology, Kanpur (IIT Kanpur) to bring new gene therapy products to the market.

The pharma company will in-license a small number of gene therapy products and offer research grants to advance them through pre-clinical development.

Laurus Labs will be responsible for launching these products in India and emerging markets.

The company will also establish a GMP facility at IIT Kanpur’s Techno Park facility.

Laurus Labs CEO Satyanarayana Chava stated: “This collaboration exhibits our commitment towards the cell and gene therapy (CGT) space.

“This partnership also provides a unique model for industry–academia collaboration and how we can leverage strengths from both sections for the benefit of patients.”

The company stated that the collaboration with IIT Kanpur allows it to strengthen its presence in the CGT space.

IITK’s department of biological sciences and bioengineering (BSBE) has been working on gene therapy for a number of years and has developed assets as well as technology for new adeno-associated virus (AAV) vectors.

IPs have been filed for these products, with additional patent applications planned to be filed soon.

Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.

Free Whitepaper

Optimise your cell therapy process: a guide to cell thawing

Typically carried out at the point of care, errors in cell therapy thawing could compromise treatment efficacy, leading to significant patient impact as well as high costs and a compromised reputation for the product’s developer. This guide addresses how cell thawing has historically developed into the new techniques used today, along with the physical and biological implications of key metrics and components such as warming rate and ice structure. Also included are reviews of key studies from scientific literature and a consideration of the interactions between cooling and warming rates, as applicable to cell and gene therapies.

By Cytiva Thematic

By downloading this case study, you acknowledge that GlobalData may share your information with Cytiva Thematic and that your personal data will be used as described in their Privacy Policy